PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Similar receivables growth to TRAW's -100.00%. Walter Schloss would see comparable credit policies, investigating any subtle differences in sales.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Other current assets growth < half of TRAW's 1250719.67%. David Dodd sees a leaner approach to short-term items.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Below half TRAW's 88788.89%. Michael Burry sees potential underinvestment risk unless there's a valid reason (asset-light model).
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Below half of TRAW's 121639.13%. Michael Burry might suspect stagnation or lack of resources for expansions.
100.00%
Higher Other Assets Growth compared to TRAW's zero value, indicating worse performance.
No Data
No Data available this quarter, please select a different quarter.
-99.84%
Less than half of TRAW's 62060.40%. David Dodd sees a more disciplined AP approach or lower volume.
-100.00%
Higher Short-Term Debt Growth compared to TRAW's zero value, indicating worse performance.
No Data
No Data available this quarter, please select a different quarter.
100.00%
Below half of TRAW's -100.00%. Michael Burry suspects a big gap in pre-sales traction.
100.00%
Less than half of TRAW's 1243893.23%. David Dodd sees fewer expansions in other current obligations.
13.77%
Less than half of TRAW's 70585.51%. David Dodd sees a more disciplined short-term liability approach.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
10.32%
Less than half of TRAW's 200.53%. David Dodd sees a more conservative approach to non-current liabilities.
No Data
No Data available this quarter, please select a different quarter.
11.40%
Less than half of TRAW's 56242.34%. David Dodd sees far fewer liability expansions relative to competitor.
No Data
No Data available this quarter, please select a different quarter.
-3.71%
Below half TRAW's -100045.78%. Michael Burry suspects major net losses or high dividends vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
110.36%
Higher Other Stockholders' Equity Items Growth compared to TRAW's zero value, indicating worse performance.
-11.42%
Below half TRAW's 137600.00%. Michael Burry sees potential underperformance in building shareholder capital.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
10.32%
Higher Total Debt Growth compared to TRAW's zero value, indicating worse performance.
10.35%
Less than half of TRAW's -81979.44%. David Dodd sees better deleveraging or stronger cash buildup than competitor.